Ruti Aga's Six-Year Ban: Two Years for the Drug, Four for the Prescription

The first number worth looking at in the Ruti Aga case is not a finishing time. It is the sum — two plus four, six in total. When the Athletics Integrity Unit issued its statement on Thursday, the six-year ban arrived split into two ledgers: two years for a prohibited substance in the sample, four years for the prescription that was meant to explain it. The date is identical in both places, 10 September. Provisional suspension from that date, sanction clock from that date. The months she has already spent out were quietly folded into the total. The figure that looks new is partly old.

The statement does not contain the time she ran to win a half marathon in China in March. No field strength, no splits, no conditions. What it contains is the fact that she won, and that the sample was collected there. I have a habit of counting strides before counting medals, but here there are no strides to count. In this story the ledger has replaced the performance, and this time the ledger is the story.

Aga is a 32-year-old Ethiopian marathoner. The record book carries her name against the 2026 Tokyo Marathon title in 2:20:40, and a second place in Berlin 2026 in 2:18:34 — that figure comes from her career sheet, not from the AIU statement. Three runner-up finishes at World Marathon Majors sit alongside it. This is the profile of a serious athlete. The profile and the case are two different documents, and I am only interested in the second one.

According to the statement, the sample taken after her March win in China returned methylprednisolone. She explained it as treatment for a knee injury and produced a prescription. The clinic that supposedly issued it did not exist. The person who described herself or himself as the doctor was a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace; the clinic named on the pad disowned it outright. Statements made during the investigation were found to be misleading. The outcome: two years for presence, four for tampering.

What the statement does not say matters just as much. The year of the March race is not given. The end year of the ban is not written out, only the start date. Whether the race result and prize money will be annulled is left open. The Ethiopian federation is not quoted. Whether the agent or management was investigated is not mentioned.

That silence is not an accident. An anti-doping statement is a narrow document: it states what was proven. So any performance conclusion drawn from the gaps is guesswork. I cannot tell you how fast she was that day. I can tell you she won, which implies a respectable elite field, because otherwise there would be no sample. Everything beyond that is inference.

The substance was not a steroid, and that is the whole case

Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List. It is not an anabolic steroid, which is S1. That distinction is not decoration — it is the spine of the matter. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The same injection is entirely legal out of competition and becomes a violation if residues are present on race day.

So the question was never the drug. It was the route and the timing. A knee injection is standard sports medicine for distance runners — intra-articular or peri-articular corticosteroid for synovitis is about as routine as it gets in a high-mileage career.

That means a legitimate defence existed. Real medical records, a dated treatment note, a documented washout period, or a therapeutic use exemption application. With those, the case is either never brought or brought at the no-fault end of the scale. The injury story is medically plausible and legally fatal, because it was manufactured rather than evidenced. That gap between two years and six years is the gap between a defence and a forgery.

The arithmetic of two and four

The Code's maths is simple. Presence of a specified substance carries a two-year standard sanction absent proof of intent. Tampering carries four. Add them and you get six. The neatness of that sum tells us something specific: the panel accepted the presence violation but granted no mitigation, and placed the documentary conduct squarely on the athlete.

Backdating to 10 September is procedure, not mercy. Time already served under provisional suspension counts against the ban; the clock was already running, so nothing was gained.

The real arithmetic is age. Six years from 32 means a return at 38. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable; a 38-year-old returning with a doping record is not selectable at all. The sanction reads as six years and functions as a career.

And here is the comparison nobody is making. Had this been a presence case alone, with a competent defence, the ban would have been two years — a return at 34, which in the marathon is not fantasy. The drug cost her two years. The paper cost her a career. That is the finding this case actually delivers, and it will be buried under headlines about steroids.

Three checks, three failures

Look closely at the prescription chain, because the AIU barely had to work. The clinic did not exist. The purported doctor held no registration. The old-pad explanation was rejected by the clinic whose name was on it. Three independent verification failures.

This was never a handwriting dispute, where experts can be called and doubt manufactured. It was an existence dispute. When the clinic is not there, there is nothing to argue about — which is why the four-year limb sits so securely.

The fourth element is heavier still. The tampering charge did not come from a document alone but from statements made in interview. Language and translation conditions in AIU interviews with Ethiopian athletes are a recurring fault line, and they will be raised again here. That does not weaken the sanction; it questions the conditions under which it was built.

And the fact that a family member played doctor is aggravating, not mitigating. An athlete who presents a relative as a physician is telling you she had nobody else to produce. That is a document of isolation. Isolation is not a defence.

The economics of a knee and the cost of being alone

The real money in marathon running is written before the start line, in appearance fees and pacing contracts and label-race prize purses. Skipping a race is not skipping a medal; it is skipping months of income. And the knee is precisely where the marathoner breaks — the first accounting failure in a career of 150-plus weekly kilometres. It is rarely an acute March event. It is a chronic problem, and the cheapest, fastest, most available fix is a corticosteroid injection. Swelling recedes, pain goes quiet for a few weeks, the race happens.

The question is not whether that was the wrong drug. The question is that nobody was there to put it on paper. What the statement reveals most clearly is the absence of a credentialed team physician: no records, no TUE application, nobody to say how many days to wait. An athlete without a team doctor becomes her own medical department, and a self-built medical department eventually produces a forged prescription.

One name is missing from the statement. The family member is named as the source; the athlete is named; the agent or manager who was selecting her races is nowhere. Athletes at this level do not choose races alone. Someone saw that document. Someone said it would hold. That someone has no line in any ledger.

Fees and testing on the same road

The March race was in China, which is itself a signal. The Chinese road-racing circuit has become a hub of deep East African elite fields and large prize purses — the income bridge between Majors, low media exposure, good money. Which is exactly why it has also become the AIU's most productive testing ground. The appearance-fee economy and the testing economy now run on the same road, and the collision is going to keep producing cases.

The in-competition window opens at 23:59 the day before the race, so an injection given days earlier is still catchable. The statement does not say whether the March result and prize money will be annulled. Standard practice is automatic disqualification of the competition where the sample was taken, plus loss of ranking points and a prize-money claim. Leaving that unsaid is itself a kind of statement.

The Indian mirror: quota, salary and a knee

My ledger is Indian, so one comparison is unavoidable. The Ethiopian marathoner's currency is the appearance fee. The Indian athlete's currency is the sports quota — Railways, Services, state police, public sector. That is the actual professional contract, because medals come and go and pay scales stay.

In 2026, when the national camp shut and the April Federation Cup was cancelled, I spent the hiatus on the phone to Railways, Services and Tamil Nadu Police officials, mapping who kept paying athletes and who quietly stopped. The lesson from that ledger applies directly here. When an athlete's livelihood is tied to a fitness certificate, the most rational treatment for an injury is to hide it. A recorded knee problem means a promotion questioned, a posting delayed, a trial missed. The incentive to conceal comes from appearance fees in Ethiopia and from pay scales in India. Different currency, identical behaviour.

The second question this case puts to India is about therapeutic use exemptions. How many Indian distance runners have ever applied for an in-competition glucocorticoid exemption? I am not claiming the number is zero; I am saying the question is not asked. Where there is no culture of applying, treatment happens off the record, and off-the-record treatment eventually produces fake paperwork.

I counted strides before I counted medals at Kalinga in July 2026, shooting Neeraj Chopra's six attempts on a borrowed lens and measuring the run-up frame by frame. The habit that produced is simple: find the metric nobody published. In this case that metric is six, not two. At Tokyo 2026 I spent two days in the mixed zone with the men's 4x400 squad after their 3:00.25 national record in the heats still left them outside the final. The lost time was not a talent failure; it was a coaching-market failure. Aga's missing element is the same shape — the absence is not in the legs, it is in the paperwork.

The contrarian read

First: the length of this ban is not the length of the drug. A glucocorticoid does not build endurance. It reduces swelling and mutes pain. She gained nothing measurable from it, and the six years she received are the length of a document. That single fact simultaneously demonstrates the AIU's rigour and exposes the disproportionality of the outcome.

Second: reading this as a doping story is the easiest route and the most misleading. The dead-ball ledger never lies; live play just distracts. Here the live play is the Chinese race, the win, the headlines. The ledger is a clinic that did not exist. Read the paperwork and you find a medical-governance failure filed under doping.

Third, and least comfortable: we all want a villain, and the family member who called himself a doctor is the obvious candidate. He is not a villain; he is the shape of an empty space. Nobody was charged for that space. No physician, no agent, no federation official appears in the statement. The sanction fell on the weakest link in the chain.

Fourth: the win carries no analytical weight because the mark is absent. That does not make the win irrelevant; it means anyone commenting on her form without a time is selling inference. I will wait for the splits before I say how fast she was.

And a question nobody asked: if tampering costs four years and presence costs two, then prescription verification should precede sample analysis. Whenever an athlete claims injury treatment, the first queries should be who wrote the prescription, where the clinic is, and whether the practitioner is registered. Run that check before the test and a good number of careers survive — and a good number of forgeries never get made.

What to watch

The CAS appeal window is open, and document-based findings are hard to overturn, but the conditions of the interview and the translation may yet be raised. The March result and its prize money remain unresolved on paper. The missing name — agent, manager, adviser — will tell us whether anti-doping systems can see beyond the athlete to the people around her. And the AIU's own direction matters most: this case reads like the moment enforcement moves from detection to document audit.

For India, a smaller question that will appear in no statement. Our selection trials still do not ask what went into an athlete's knee last month, who put it there, and where the record is. Every shutdown invents a quota economy, and every quota economy hides a queue. The people standing in that queue are not waiting for a medal. They are waiting for a piece of paper that keeps them in the sport.

What would have happened if Ruti Aga had a team doctor, a filed record, and a prescription that could be verified? The most frightening answer is that nothing would have happened at all. The saddest is that she had none of it, so everything did.